U2AF1 and cancer: Therefore, given the vulnerability of hematopoietic cells with spliceosome mutations, selectively targeting the U2AF1WT allele in heterozygous mutant cells has the potential to therapeutically induce cancer cell death in patients with U2AF1 mutations [71].